The comparison of dual phase Tc-99m MIBI and Tc-99m MDP scintimammography in the evaluation of breast masses: Preliminary report

Annals of Nuclear Medicine

Volumn 14, Issue 1, 2000, Pages 39-46

  Arslan, Nuri ^a   Ozturk, Emel ^a   Ilgan, Seyfettin ^a   Narin, Yavuz ^a   Dundar, Sabri ^a   Tufan, Turgut ^a   Pekcan, Mesut ^a   Bayhan, Hikmet ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

Breast cancer; Scintimammography; Tc 99m MDP; Tc 99m MIBI

Indexed keywords

MEDRONATE TECHNETIUM TC 99M; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BONE METASTASIS; BREAST CANCER; BREAST TUMOR; CANCER DIAGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAMMOGRAPHY; PRIORITY JOURNAL; SCINTIMAMMOGRAPHY;

EID: 0034125519     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02990477     Document Type: Article

References (20)

1. Robert AS. The epidemiology of breast cancer. In Daniel BK, Ellen BM (eds.): Syllabus: A.categorical course in breast imaging. 81st scientific assembly and annual meeting of the Radiological Society of North America, pp. 7-20, November 26-December 1, 1995.
2. Kopans DB. The positive predictive value of mammography. AJR 158:521, 1992.
3. Savi A, Gerundini P, Zoli P, et al. Biodistribution of Tc-99m Methoxy-Isobutyl-Isonitrile (MIBI) in Humans. Eur J Nucl Med 15: 597, 1989.
4. Khalkhali I, Cutrone JA, Mena IG, et al. Scintimammography: The complementary role of Tc-99m sestamibi prone breast imaging for the diagnosis of breast carcinoma. Radiology 196:421, 1995.
5. Taillefer R, Robidoux A, Lambert R, et al. Technetium-99m-Sestamibi prone scintimammography to detect primary breast cancer and axillary lymph node involvement. J Nucl Med 36: 1758, 1995.
6. Villanueva-Meyer JV, Leonard MH Jr, Briscoe E, et al. Mammoscintigraphy with Technetium-99m-Sestamibi in Suspected Breast Cancer. J Nud Med 37: 926, 1996.
7. Palmedo H, Schomburg A, Grunwald F, et al. Technetium-99m-MIBI scintimammography for suspicious breast lesions. J Nucl Med 37: 626, 1996.
8. Khalkhali I, Cutrone J, Mena I, et al. Technetium-99m-sestamibi scintimammography of breast lesions: clinical and pathologic follow-up. J Nucl Med 36: 1784, 1995.
9. Berg GR, Kalisher L, Osmond JD, et al. 99m-Tc-diphosphonate concentration in primary breast carcinoma. Radiology 109: 393, 1973.
10. Mc Dougall IR, Pistenma DA. Concentration of 99m-Tc-diphosphonate in breast tissue. Radiology 112: 655, 1974.
11. Schmitt GH, Holmes RA, Isitman AT, et al. A proposed mechanism for Tc-99m-labeled polyphosphate and diphosphonate uptake by human breast tissue. Radiology 112: 733, 1974.
12. Burnett KR, Lyons KP, Brown WT. Uptake of osteotropic radionuclides in the breast. Semin Nucl Med 14: 48, 1984.
13. Hobbs S, Neumann RD, Merino MJ, Gunzenhauser J, Carrasquillo JA. Localization of Tc-99m-MDP in cystosarcoma phyllodes. Clin Nucl Med 17: 58, 1992.
14. Serafini AN, Raskin MM, Zand LC, et al. Radionuclide breast scanning in carcinoma of the breast. J Nucl Med 15: 1149, 1974.
15. Piccolo S, Lastoria S, Mainolfi C, et al. Technetium-99m-methylene diphosphonate scintimammography to image primary breast cancer. J Nucl Med 36: 718, 1995.
16. Worsley DF, Lentle BC. Uptake of technetium-99m MDP in primary amyloidosis with a review of the mechanisms of soft-tissue localization of bone seeking radiopharmaceuticals. J Nucl Med 34: 1612, 1993.
17. Lastoria S, Piccolo S, Varrella P, et al. Comparative results of Tc-99m MIBI andTc-99m MDP scintimammography in patients with breast abnormalities. J Nucl Med 36 (suppl): 51, 1995. (abstract)
18. Pi wnica-Worms D, Chiu ML, Budding M, et al. Functional imaging of multidrug-resistant P-glycoprotein with an organo-technetium complex. Cancer Res 53: 977, 1993.
19. Moretti JL, Caglar M, Duran-Cordobes M, Morere JF, et al. Can nuclear medicine predict response to chemotherapy? Eur J Nucl Med 22: 97, 1995.
20. Vecchio SD, Ciarmiello A, Potena MI, et al. In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients. Eur J Nucl Med 24: 150, 1997.